Clinical Trial Update: Moroctocog Alfa (AF-CC) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Hemophilia A Patients [Phase 4]

View source ↗

Summary

Phase 4 trial update for Moroctocog Alfa (AF-CC) in prophylaxis and treatment of bleeding episodes in previously treated Hemophilia A patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Moroctocog alfa AF-CC (moroctocog alfa)

Snippet

Sponsor: Pfizer | Conditions: Hemophilia A | Phase 4 | Status: COMPLETED | Results posted: 2021-05-03